Brokers Issue Forecasts for TMDX Q1 Earnings

TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) - Investment analysts at William Blair issued their Q1 2026 EPS estimates for shares of TransMedics Group in a report issued on Wednesday, July 9th. William Blair analyst R. Daniels anticipates that the company will earn $0.63 per share for the quarter. The consensus estimate for TransMedics Group's current full-year earnings is $1.00 per share. William Blair also issued estimates for TransMedics Group's Q2 2026 earnings at $0.59 EPS, Q3 2026 earnings at $0.51 EPS and Q4 2026 earnings at $0.58 EPS.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.29 by $0.41. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The firm had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. During the same quarter last year, the firm posted $0.35 earnings per share. TransMedics Group's revenue for the quarter was up 48.2% compared to the same quarter last year.

Other equities analysts have also recently issued research reports about the company. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Oppenheimer lifted their target price on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $127.33.

TransMedics Group Trading Down 1.3%

Shares of TMDX opened at $124.78 on Friday. The company has a current ratio of 9.10, a quick ratio of 8.32 and a debt-to-equity ratio of 1.92. TransMedics Group has a 1-year low of $55.00 and a 1-year high of $177.37. The business's 50-day moving average price is $125.04 and its 200 day moving average price is $90.13. The stock has a market capitalization of $4.22 billion, a P/E ratio of 91.75 and a beta of 2.06.

Insider Transactions at TransMedics Group

In other news, Director Edward M. Basile sold 5,000 shares of the firm's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the sale, the director owned 2,866 shares of the company's stock, valued at $362,405.70. This trade represents a 63.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David Weill sold 732 shares of the stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the transaction, the director owned 12,134 shares of the company's stock, valued at approximately $1,503,159.92. The trade was a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,418 shares of company stock valued at $1,512,613 over the last 90 days. 7.00% of the stock is owned by company insiders.

Institutional Trading of TransMedics Group

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in TransMedics Group by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock valued at $226,700,000 after acquiring an additional 40,860 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in TransMedics Group by 244.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock valued at $209,448,000 after acquiring an additional 2,209,996 shares in the last quarter. FIL Ltd raised its holdings in TransMedics Group by 28.0% in the 4th quarter. FIL Ltd now owns 1,000,358 shares of the company's stock valued at $62,372,000 after acquiring an additional 218,961 shares in the last quarter. Braidwell LP acquired a new position in TransMedics Group in the 4th quarter valued at $57,493,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in TransMedics Group by 16.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company's stock valued at $56,307,000 after acquiring an additional 128,474 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.